CY1119337T1 - Βιοαποικοδομησιμα μικροσφαιριδια με βελτιωμενη προσροφητικοτητα αντικαρκινικου φαρμακου, που περιεχουν αλβουμινη και θειικη δεξτρανη και μεθοδος παρασκευης αυτων - Google Patents
Βιοαποικοδομησιμα μικροσφαιριδια με βελτιωμενη προσροφητικοτητα αντικαρκινικου φαρμακου, που περιεχουν αλβουμινη και θειικη δεξτρανη και μεθοδος παρασκευης αυτωνInfo
- Publication number
- CY1119337T1 CY1119337T1 CY20171100962T CY171100962T CY1119337T1 CY 1119337 T1 CY1119337 T1 CY 1119337T1 CY 20171100962 T CY20171100962 T CY 20171100962T CY 171100962 T CY171100962 T CY 171100962T CY 1119337 T1 CY1119337 T1 CY 1119337T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dextran
- improved anti
- cancer
- containing aluminum
- biodegradable microspheres
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε: βιοαποικοδομήσιμα μικροσφαιρίδια με βελτιωμένη προσροφητικότητα αντικαρκινικού φαρμάκου, που περιέχουν αλβουμίνη και θειϊκή δεξτράνη˙ μία μέθοδο παρασκευής αυτών˙ και μία μέθοδο για θεραπευτική αγωγή καρκίνου χρησιμοποιώντας αυτά. Τα μικροσφαιρίδια της παρούσας εφεύρεσης παρασκευάζονται από ένα βιοσυμβατό και βιοαποικοδομήσιμο πολυμερές έτσι ώστε να είναι ασφαλή για το ανθρώπινο σώμα και μπορούν να αναστείλουν αποτελεσματικά την ανάπτυξη ενός όγκου με αποτελεσματικό αποκλεισμό ενός αιμοφόρου αγγείου το οποίον παρέχει διατροφή σε έναν όγκο ήπατος και απελευθερώνοντας συνεχώς ένα αντικαρκινικό φάρμακο προσροφημένο στις επιφάνειες των σφαιριδίων. Επομένως, η παρούσα εφεύρεση μπορεί να είναι χρήσιμη για τον χημειοεμβολισμό καρκίνου ήπατος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120129722 | 2012-11-15 | ||
PCT/KR2013/010419 WO2014077629A1 (ko) | 2012-11-15 | 2013-11-15 | 알부민 및 덱스트란 설페이트를 포함하는 항암제 흡착능력이 향상된 생분해성 마이크로 비드 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119337T1 true CY1119337T1 (el) | 2018-02-14 |
Family
ID=50731466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100962T CY1119337T1 (el) | 2012-11-15 | 2017-09-12 | Βιοαποικοδομησιμα μικροσφαιριδια με βελτιωμενη προσροφητικοτητα αντικαρκινικου φαρμακου, που περιεχουν αλβουμινη και θειικη δεξτρανη και μεθοδος παρασκευης αυτων |
Country Status (16)
Country | Link |
---|---|
US (2) | US20150352050A1 (el) |
EP (1) | EP2921166B1 (el) |
JP (1) | JP6145513B2 (el) |
KR (1) | KR101563968B1 (el) |
CN (1) | CN104780912B (el) |
CY (1) | CY1119337T1 (el) |
DK (1) | DK2921166T3 (el) |
ES (1) | ES2640363T3 (el) |
HR (1) | HRP20171364T1 (el) |
HU (1) | HUE036275T2 (el) |
LT (1) | LT2921166T (el) |
PL (1) | PL2921166T3 (el) |
PT (1) | PT2921166T (el) |
RS (1) | RS56295B1 (el) |
SI (1) | SI2921166T1 (el) |
WO (1) | WO2014077629A1 (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6049901B2 (ja) * | 2012-11-27 | 2016-12-21 | ユタ−イナ ディーディーエス アンド アドバンスト セラピューティクス リサーチ センター | 陰イオン性高分子を含む抗癌剤吸着能力の向上された生分解性マイクロビーズ及びその製造方法 |
CN109010902A (zh) * | 2018-05-04 | 2018-12-18 | 南京大学 | 一种具有抗肿瘤作用的肝素淀粉微球血管栓塞剂及制备方法 |
KR102097401B1 (ko) * | 2018-10-10 | 2020-04-06 | 인제대학교 산학협력단 | 정전기적 결합을 통한 약물-고분자 복합체 및 이의 제조방법 |
JP7198529B2 (ja) * | 2018-11-30 | 2023-01-04 | ネクストバイオメディカル カンパニー リミテッド | 生分解性高分子を含む化学塞栓用水和ゲル粒子 |
WO2020116831A1 (ko) * | 2018-12-05 | 2020-06-11 | 주식회사 이노테라피 | 간동맥 화학색전술용 마이크로비드 및 그의 제조방법 |
KR102288833B1 (ko) * | 2019-09-11 | 2021-08-13 | 주식회사 메피온 | 자가 팽창형 색전물질의 제조 방법 |
KR102641217B1 (ko) * | 2019-12-24 | 2024-02-29 | (주)아이엠지티 | 항암제가 코팅된 알부민 나노입자 및 이의 제조방법 |
KR102373590B1 (ko) * | 2020-09-22 | 2022-03-14 | (주)아이엠지티 | 음이온성 고분자를 이용한 신규한 나노 입자, 이의 제조 방법 및 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1077842A (en) * | 1975-10-09 | 1980-05-20 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
US5041292A (en) * | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
EP0693924B2 (en) * | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US6090925A (en) * | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5578709A (en) * | 1993-03-09 | 1996-11-26 | Middlesex Sciences, Inc. | Macromolecular microparticles and methods of production |
DE69432867T2 (de) * | 1993-11-18 | 2004-04-22 | Sirtex Medical Ltd., Burswood | Zubereitung mit gesteuerter freisetzung |
IL133672A0 (en) * | 1997-06-27 | 2001-04-30 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20040161466A1 (en) | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
EP3085361A1 (en) * | 2004-09-07 | 2016-10-26 | Biocompatibles UK Limited | Compositions comprising camptothecins in microspheres |
JP4654815B2 (ja) * | 2005-07-26 | 2011-03-23 | アイシン精機株式会社 | 車両用ヘッドレスト装置 |
US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
JP6049901B2 (ja) * | 2012-11-27 | 2016-12-21 | ユタ−イナ ディーディーエス アンド アドバンスト セラピューティクス リサーチ センター | 陰イオン性高分子を含む抗癌剤吸着能力の向上された生分解性マイクロビーズ及びその製造方法 |
US9833405B2 (en) * | 2014-03-19 | 2017-12-05 | Nano And Advanced Materials Institute Limited | Biodegradable microdepot delivery system for topical delivery |
-
2013
- 2013-11-15 PT PT138549910T patent/PT2921166T/pt unknown
- 2013-11-15 HU HUE13854991A patent/HUE036275T2/hu unknown
- 2013-11-15 RS RS20170900A patent/RS56295B1/sr unknown
- 2013-11-15 EP EP13854991.0A patent/EP2921166B1/en active Active
- 2013-11-15 PL PL13854991T patent/PL2921166T3/pl unknown
- 2013-11-15 DK DK13854991.0T patent/DK2921166T3/en active
- 2013-11-15 KR KR1020130139303A patent/KR101563968B1/ko active IP Right Grant
- 2013-11-15 ES ES13854991.0T patent/ES2640363T3/es active Active
- 2013-11-15 WO PCT/KR2013/010419 patent/WO2014077629A1/ko active Application Filing
- 2013-11-15 LT LTEP13854991.0T patent/LT2921166T/lt unknown
- 2013-11-15 SI SI201330775T patent/SI2921166T1/sl unknown
- 2013-11-15 CN CN201380059670.4A patent/CN104780912B/zh active Active
- 2013-11-15 JP JP2015542954A patent/JP6145513B2/ja not_active Expired - Fee Related
- 2013-11-15 US US14/442,901 patent/US20150352050A1/en not_active Abandoned
-
2017
- 2017-09-12 CY CY20171100962T patent/CY1119337T1/el unknown
- 2017-09-12 HR HRP20171364TT patent/HRP20171364T1/hr unknown
-
2019
- 2019-05-07 US US16/405,540 patent/US20190274957A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2921166B1 (en) | 2017-06-14 |
EP2921166A4 (en) | 2016-04-20 |
CN104780912B (zh) | 2018-03-30 |
DK2921166T3 (en) | 2017-10-02 |
LT2921166T (lt) | 2017-09-25 |
US20190274957A1 (en) | 2019-09-12 |
ES2640363T3 (es) | 2017-11-02 |
HUE036275T2 (hu) | 2018-06-28 |
EP2921166A1 (en) | 2015-09-23 |
US20150352050A1 (en) | 2015-12-10 |
JP6145513B2 (ja) | 2017-06-14 |
HRP20171364T1 (hr) | 2017-11-03 |
CN104780912A (zh) | 2015-07-15 |
KR20140066099A (ko) | 2014-05-30 |
WO2014077629A1 (ko) | 2014-05-22 |
PL2921166T3 (pl) | 2017-11-30 |
SI2921166T1 (sl) | 2017-10-30 |
JP2016505530A (ja) | 2016-02-25 |
KR101563968B1 (ko) | 2015-10-29 |
RS56295B1 (sr) | 2017-12-29 |
PT2921166T (pt) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119337T1 (el) | Βιοαποικοδομησιμα μικροσφαιριδια με βελτιωμενη προσροφητικοτητα αντικαρκινικου φαρμακου, που περιεχουν αλβουμινη και θειικη δεξτρανη και μεθοδος παρασκευης αυτων | |
CY1120547T1 (el) | Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας | |
CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
CY1121838T1 (el) | Συνθεσεις που περιλαμβανουν νανοσωματιδια οξειδιου του αφνιου (iv) ή οξειδιου του ρηνιου (iv) σε συνδυασμο με ιονιζουσες ακτινοβολιες για αντιμετωπιση καρκινου | |
BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
EP2844736A4 (en) | Modified bacteria and uses thereof for the treatment of carcinomas or tumors | |
NZ722768A (en) | Use of alphavirus in preparation of antitumor drugs | |
BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
BR112016000853A2 (pt) | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit | |
EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112018075660A2 (pt) | métodos de tratamento de câncer de pâncreas | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
CR20120035A (es) | Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona | |
WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
EA201491427A1 (ru) | Замещенные фенилимидазопиразолы и их применение | |
WO2015022530A3 (en) | Materials and methods relating to pancreatic cancer | |
CY1120075T1 (el) | Καρβορανυλο-πορφυρινες για χρηση στη θεραπεια του καρκινου | |
WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
EA201892631A1 (ru) | Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака |